Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Caveney

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Advances in Therapy|November 18, 2024
Predicting Asthma Exacerbations Using Machine Learning ModelsGianluca Turcatel, Yi Xiao, Scott Caveney, et al.
Skinmed|July 12, 2012
A comparison of the tolerability of adapalene 0.1% cream and adapalene 0.1% lotion in healthy individualsJames H Herndon, Thomas J Stephens, Nathan S Trookman, et al.
Pulmonary Therapy|December 8, 2023
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR StudyJeremy Cole, Iwona Cąpała-Szczurko, Stephanie Roseti, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 10, 2024
Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATIONMichael E Wechsler, Daiana Stolz, Njira L Lugogo, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 1, 2021
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical TrialsNicola A Hanania, Scott Caveney, Tedi Soule, et al.
Clinical and Experimental Immunology|September 8, 2025
Thymic stromal lymphopoietin as a therapeutic target in patients with chronic rhinosinusitis and nasal polypsAnju T Peters, Joseph K Han, Enrico Heffler, et al.
Advances in Therapy|November 8, 2024
Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal PolypsJoshua S Jacobs, Joseph K Han, Jason K Lee, et al.
Journal of Asthma and Allergy|September 11, 2023
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATORTanya M Laidlaw, Andrew Menzies-Gow, Scott Caveney, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 2, 2024
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION studyChristopher E Brightling, Marco Caminati, Jean-Pierre Llanos, et al.
The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Advances in Therapy|November 18, 2024
Predicting Asthma Exacerbations Using Machine Learning ModelsGianluca Turcatel, Yi Xiao, Scott Caveney, et al.
Skinmed|July 12, 2012
A comparison of the tolerability of adapalene 0.1% cream and adapalene 0.1% lotion in healthy individualsJames H Herndon, Thomas J Stephens, Nathan S Trookman, et al.
Pulmonary Therapy|December 8, 2023
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR StudyJeremy Cole, Iwona Cąpała-Szczurko, Stephanie Roseti, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 10, 2024
Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATIONMichael E Wechsler, Daiana Stolz, Njira L Lugogo, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 1, 2021
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical TrialsNicola A Hanania, Scott Caveney, Tedi Soule, et al.
Clinical and Experimental Immunology|September 8, 2025
Thymic stromal lymphopoietin as a therapeutic target in patients with chronic rhinosinusitis and nasal polypsAnju T Peters, Joseph K Han, Enrico Heffler, et al.
Advances in Therapy|November 8, 2024
Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal PolypsJoshua S Jacobs, Joseph K Han, Jason K Lee, et al.
Journal of Asthma and Allergy|September 11, 2023
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATORTanya M Laidlaw, Andrew Menzies-Gow, Scott Caveney, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 2, 2024
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION studyChristopher E Brightling, Marco Caminati, Jean-Pierre Llanos, et al.
The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.
Pageof 1